Which scenario would indicate the use of PCSK9 inhibitors?

Which scenario would indicate the use of PCSK9 inhibitors?

• A. Patient not meeting LDL-C goals despite maximally tolerated statin therapy
• B. Patient with low LDL-C
• C. Patient with high HDL only
• D. Patient with high triglycerides with normal LDL-C

Answer: (A)

The scenario best calling for a PCSK9 inhibitor is when LDL-C remains above goal despite maximally tolerated statin therapy. PCSK9 inhibitors work by blocking PCSK9, which normally degrades LDL receptors. With more LDL receptors available, the liver clears more LDL-C from the blood, allowing for additional lowering beyond what statins alone achieve. This makes them a logical next step for patients at high cardiovascular risk who still don’t reach their LDL-C target on statins (often used in combination with ezetimibe as needed). The other situations aren’t appropriate for initiating a PCSK9 inhibitor because they don’t reflect a need for further LDL-C reduction: having low LDL-C means no further lowering is required; high HDL by itself isn’t the target for PCSK9 inhibitors; and high triglycerides with normal LDL-C are not addressed by PCSK9 inhibitors, which primarily lower LDL-C rather than triglycerides or HDL.

The scenario best calling for a PCSK9 inhibitor is when LDL-C remains above goal despite maximally tolerated statin therapy. PCSK9 inhibitors work by blocking PCSK9, which normally degrades LDL receptors. With more LDL receptors available, the liver clears more LDL-C from the blood, allowing for additional lowering beyond what statins alone achieve. This makes them a logical next step for patients at high cardiovascular risk who still don’t reach their LDL-C target on statins (often used in combination with ezetimibe as needed).

The other situations aren’t appropriate for initiating a PCSK9 inhibitor because they don’t reflect a need for further LDL-C reduction: having low LDL-C means no further lowering is required; high HDL by itself isn’t the target for PCSK9 inhibitors; and high triglycerides with normal LDL-C are not addressed by PCSK9 inhibitors, which primarily lower LDL-C rather than triglycerides or HDL.